Cardiovascular Outcomes with Empagliflozin – News for Type 2 Diabetes Therapy

Cardiovascular safety has to be proven for antidiabetic therapy for type 2 diabetes according to the guidance from regulatory bodies. Recently, the results of the respective study for the sodium-glucose transporter-2 (SGLT-2) inhibitor empagliflozin were published. Unlike similar studies for other a...

Descripción completa

Detalles Bibliográficos
Autor principal: Gallwitz, Baptist
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Touch Medical Media 2016
Materias:
Diabetes Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5813455/
https://www.ncbi.nlm.nih.gov/pubmed/29632584
http://dx.doi.org/10.17925/EE.2016.12.01.31

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5813455/
https://www.ncbi.nlm.nih.gov/pubmed/29632584
http://dx.doi.org/10.17925/EE.2016.12.01.31

Ejemplares similares